
Sign up to save your podcasts
Or


14 million Americans suffer migraine headaches every day. Many go untreated and many who are treated continue to have headaches. But an old drug proved to offer a new way to treat migraines, with the FDA approval of botulinum toxin injections for severe chronic migraine. Dr. David Simpson, professor of neurology at Mount Sinai School of Medicine in New York City and director of the clinical neurophysiology lab at Mount Sinai Hospital, joins host Dr. Anthony Alessi to discuss what patients qualify for this treatment, problems and risks associated with taking the injections, and the controversial results of the earlier clinical trials for this treatment.
By ReachMD14 million Americans suffer migraine headaches every day. Many go untreated and many who are treated continue to have headaches. But an old drug proved to offer a new way to treat migraines, with the FDA approval of botulinum toxin injections for severe chronic migraine. Dr. David Simpson, professor of neurology at Mount Sinai School of Medicine in New York City and director of the clinical neurophysiology lab at Mount Sinai Hospital, joins host Dr. Anthony Alessi to discuss what patients qualify for this treatment, problems and risks associated with taking the injections, and the controversial results of the earlier clinical trials for this treatment.

91,297 Listeners

43,837 Listeners

299 Listeners

3,968 Listeners

113,121 Listeners

24 Listeners

134 Listeners

96 Listeners

80 Listeners